Knee pain is the most common reason for activity limitation in American adults, and the treatments most people cycle through all carry significant constraints: anti-inflammatory medication, cortisone injections, physical therapy, and eventually the prospect of joint replacement. Red light therapy (clinically known as photobiomodulation) operates at a fundamentally different level, targeting the cellular biology of the knee joint itself. A 2025 network meta-analysis of 32 randomized controlled trials comparing every major physical therapy modality head-to-head ranked low-level light therapy as the single most effective intervention for knee pain reduction and joint function improvement, outperforming electrical stimulation, shockwave therapy, thermotherapy, cryotherapy, and ultrasound. A 2025 umbrella review synthesizing 204 RCTs across all health conditions found moderate certainty evidence supporting photobiomodulation for knee osteoarthritis disability improvement, placing it among the strongest evidence domains identified for this therapy overall.
The research base behind these conclusions is extensive. More than 30 randomized controlled trials for knee osteoarthritis alone, with additional clinical studies covering meniscal tears, patellofemoral pain, post-surgical recovery, tendinopathy, and rheumatoid arthritis. Multiple systematic reviews and a growing body of molecular evidence show that the therapy intervenes in the inflammatory and degenerative processes driving knee pain rather than masking the pain signal.
This article is the hub for our complete guide to Red and Infrared Light Therapy for Knee Pain. For condition-specific studies, mechanisms, clinical evidence, safety data, and device considerations, follow the links to each deep-dive article throughout.
Key Takeaways
- Ranked #1 among physical therapies for knee pain: A 2025 network meta-analysis of 32 RCTs and 2,078 participants found that low-level light therapy demonstrated the highest efficacy for both pain reduction and joint function improvement among all physical modalities tested for knee osteoarthritis, including electrical stimulation, shockwave therapy, thermotherapy, and ultrasound.
- Strong evidence across multiple review levels: A 2025 umbrella review of 204 RCTs rated the evidence for photobiomodulation in knee OA disability at moderate certainty. A separate network meta-analysis of 13 RCTs identified near-infrared wavelengths (904–905nm) as most effective for pain reduction, with both infrared and red wavelength ranges significantly outperforming sham treatment.
- Benefits sustained at 6 and 12 months: A 168-patient, double-blind RCT found that photobiomodulation reduced pain at rest versus placebo at every follow-up through 6 months. A separate placebo-controlled trial combining photobiomodulation with strength training found significantly reduced pain-medication use and improved sit-to-stand performance versus placebo at 12 months.
What Knee Pain Does and Why Current Options Leave a Gap
The knee is the most commonly affected joint in osteoarthritis. The numbers behind that distinction are sobering. A 2023 analysis for the Global Burden of Disease Study published in The Lancet Rheumatology estimated 595 million people globally live with osteoarthritis, with knee OA as the most common site and a projected 74.9% increase in cases by 2050. In the United States alone, 14 million Americans have symptomatic knee osteoarthritis, and more than half are under 65. Over half of those diagnosed will eventually undergo total knee replacement. 4 million Americans are currently living with an artificial knee.
The standard treatment path manages symptoms while the joint continues to deteriorate underneath. NSAIDs reduce pain during flare-ups but carry gastrointestinal, cardiovascular, and renal risks with sustained use, and they do nothing to slow cartilage breakdown. Cortisone injections lose effectiveness with repetition. Physical therapy strengthens the supporting musculature, which genuinely helps, but it cannot rebuild cartilage that has already degraded. Joint replacement surgery works for end-stage disease but involves months of recovery and is not appropriate for the millions of people living between medication management and surgical intervention.
That gap is where the photobiomodulation research is strongest. The therapy reaches the biology of the joint itself: restoring cellular energy, reducing the inflammatory signals that drive cartilage destruction, suppressing the specific enzymes that dissolve cartilage from within, and modulating pain signaling at the nerve level. The foundational mechanisms are covered in the complete guide to how red light therapy works. The question for knee pain specifically is how those mechanisms interact with the particular biology of the joint.
How Red Light Therapy Works for Knee Pain
Red light at wavelengths typically between 630 and 660nm stimulates a key enzyme in the mitochondria (cytochrome c oxidase), increasing cellular energy production in tissue that chronic inflammation has left energy-depleted. The downstream effects are well characterized: reduced inflammatory signaling, lower oxidative stress, and enhanced cellular repair capacity. For knee joints specifically, this means the chondrocytes (cartilage cells), synoviocytes (joint lining cells), and tenocytes (tendon cells) that have been running on depleted energy reserves can resume their maintenance and repair functions.
The biomarker data moves the mechanism from theoretical to measured. A 2026 placebo-controlled pilot study analyzed biomarkers directly in the knee joints of OA patients and found that photobiomodulation significantly reduced IL-1, IL-6, TNF-α, and prostaglandin E2 in blood, while lowering MMP-3, MMP-13, and the cartilage breakdown marker CTX-II in synovial fluid. The study was small, which means the specific magnitudes carry less weight than the direction; but a placebo-controlled trial documenting enzymatic changes in actual knee joint fluid is a fundamentally different kind of data than another pain questionnaire.
(For the complete evidence on red light mechanisms, see Red Light Benefits for Knee Pain.)
How Infrared Light Therapy Works for Knee Pain
Near-infrared light at wavelengths between 808 and 905nm penetrates deeper into tissue, reaching the cartilage, meniscus, tendons, and subchondral bone structures where knee pain originates. Fan et al.'s 2024 network meta-analysis of 13 RCTs tested a question the field needed answered: which specific wavelengths produce the strongest outcomes? The 904–905nm range ranked most effective for pain reduction (SUCRA 86.9%), with both 904–905nm and 785–850nm significantly outperforming sham treatment.
Deeper tissue penetration matters for the knee because the joint structures driving pain (articular cartilage, menisci, synovial membrane, subchondral bone) sit beneath skin, subcutaneous tissue, and muscle layers that attenuate light energy before it reaches the target. Getting sufficient photon density to those structures is the central engineering challenge, and it is why wavelength selection and power density are clinical variables, not marketing details.
(For the complete evidence on infrared light mechanisms, see Infrared Light Benefits for Knee Pain.)
What the Clinical Evidence Shows
The clinical evidence for photobiomodulation in knee pain spans more than two decades and multiple review levels: network meta-analyses, umbrella reviews, systematic reviews, and individual RCTs conducted across multiple countries.
The 2025 network meta-analysis by Lan et al., published in Aging Clinical and Experimental Research, pooled 32 RCTs with 2,078 participants and compared low-level light therapy directly against electrical stimulation, extracorporeal shockwave therapy, thermotherapy, cryotherapy, and ultrasound. Low-level light therapy demonstrated the highest efficacy for pain reduction on both VAS and WOMAC pain measures, and ranked highest for joint function improvement (SUCRA 79.8). Shockwave therapy ranked second for pain; ultrasound showed no significant benefit.
Li et al.'s 2023 meta-analysis in Archives of Physical Medicine and Rehabilitation asked a more practical question: what happens when you add photobiomodulation to exercise? Across 14 pooled RCTs, the combination significantly improved WOMAC total, WOMAC pain, WOMAC function, VAS pain, and knee range of motion in older adults compared to exercise alone.
The largest individual RCT tells a straightforward story. Alqualo-Costa et al. (2021) enrolled 168 patients into a four-arm, double-blind design. Photobiomodulation alone reduced pain at rest versus placebo at every follow-up point through 6 months. When combined with interferential current therapy, the results were stronger still.
(For the complete clinical evidence, see PBM for Knee Pain: Clinical Evidence.)
Which Types of Knee Pain Respond Best, and Where Is the Evidence Still Building?
Knee pain has multiple causes, and the research evidence varies by condition. The evidence ratings below help you evaluate the strength of the science behind photobiomodulation for each condition:
★★★★★ Gold Standard — Multiple human RCTs, systematic reviews, or meta-analyses with consistent findings.
★★★★ Strong — At least one well-designed human RCT or multiple controlled studies with significant outcomes.
★★★ Moderate — Human clinical studies with positive outcomes, supported by strong animal or cell-level evidence.
★★ Emerging — Strong biological rationale with limited condition-specific clinical data. Mechanism well-established; clinical confirmation still building.
Osteoarthritis / Degenerative Joint Disease
Evidence Rating: ★★★★★ Gold Standard
This is where the evidence is deepest. Multiple meta-analyses, network meta-analyses, and dozens of individual RCTs confirm significant pain reduction, improved function, and reduced medication use. The 2019 BMJ Open meta-analysis by Stausholm et al. established the dose-response relationship across 22 placebo-controlled trials: adequate irradiance at appropriate wavelengths produces significant pain relief; underpowered protocols do not. The 2025 Lan et al. network meta-analysis ranked photobiomodulation first among all physical modalities.
The molecular evidence has caught up to the clinical findings. The 2026 Ferreira et al. pilot study documented reduced cartilage-degrading enzymes (MMP-3, MMP-13) and inflammatory cytokines (IL-1, IL-6, TNF-α) directly in knee joint fluid. And Wang et al. (2025) demonstrated a specific mechanism: photobiomodulation shifts destructive M1 macrophages toward reparative M2 macrophages in osteoarthritic joint tissue through the IL-6/JAK/STAT pathway, directly reducing the immune-driven cartilage destruction at the heart of the disease.
What to expect: The 2024 Oliveira et al. systematic review quantified what the clinical trials actually deliver. Pain at rest improved by up to 4 points on the 10-point VAS scale after treatment, and pain during activity improved by up to 5.8 points, exceeding the threshold for a clinically meaningful difference by 160% and 232% respectively. WOMAC function scores improved by an average of 6.8 points, nearly five times the minimum clinically important difference. In the Alqualo-Costa trial, these improvements held through 6 months. In the Stausholm trial, reduced medication use persisted at 12 months.
A person using photobiomodulation consistently for knee OA can reasonably expect meaningful pain reduction within 2–4 weeks, progressive functional improvement over 8–12 weeks, and sustained benefits that build with continued use. The effects are cumulative rather than session-limited because the therapy addresses the inflammatory biology driving the disease. Calling it "disease-modifying" would be premature on the basis of one pilot study measuring enzymatic changes, but the direction of the biomarker evidence and the durability of the clinical outcomes both point toward a therapy that does more than manage symptoms. The therapy's demonstrated value is in slowing the enzymatic destruction that drives ongoing cartilage loss; it does not reverse structural damage already sustained.
Meniscal Tears (Degenerative)
Evidence Rating: ★★★ Moderate
The evidence here rests on one well-designed trial and supporting mechanistic data. Malliaropoulos et al. (2013) ran the only sham-controlled RCT specifically for meniscal pathology. It was double-blind and placebo-controlled, and the results were clear: pain improved significantly in the treatment group versus placebo, with an 87.5% response rate and benefits maintained at 6 months and 1 year. Lysholm knee function scores also improved significantly. The authors concluded that photobiomodulation should be considered for meniscal tears in patients who do not wish to undergo surgery. Nakamura et al. (2014) treated 35 patients with chronic knee pain from OA-induced degenerative meniscal tears and found significant pain improvement after 4 weeks of 830nm near-infrared treatment.
On the mechanistic side, Tong et al. (2025) established that photobiomodulation stimulates meniscus-derived stem cell proliferation through TRPV1 signaling, providing the cellular basis for meniscal tissue support.
The Malliaropoulos data sets a realistic benchmark: nearly 9 in 10 patients responded, with benefits lasting at least a year. For someone with a degenerative meniscal tear who is managing conservatively rather than pursuing surgery, this is a well-supported non-surgical option. It is one trial, and the cellular mechanism (meniscal stem cell activation) provides biological plausibility for tissue-level support beyond pain relief, but meniscal regrowth in humans has not been demonstrated. Expect meaningful pain relief and functional improvement. Do not expect structural meniscal repair based on current evidence.
Patellofemoral Pain Syndrome (Anterior Knee Pain)
Evidence Rating: ★★★ Moderate
Until recently, no one had tested photobiomodulation for anterior knee pain in a non-OA population. Gavish et al. (2021) changed that with a double-blind, sham-controlled RCT in combat soldiers. Photobiomodulation plus physiotherapy significantly reduced pain versus sham plus physiotherapy at 4 weeks, and functional scores (Kujala) improved significantly only in the treatment group at 3-month follow-up. Pocai et al. (2021) enrolled 30 young women with patellofemoral pain and found significant pain reduction for jump landing activities, with questionnaire effect sizes favoring the treatment group. A 2025 systematic review and meta-analysis now provides the first pooled assessment for this specific condition.
For someone with anterior knee pain from patellofemoral overuse, runner's knee, or chondromalacia patellae, photobiomodulation is a reasonable addition to a physiotherapy program. That the Gavish results came from a physically demanding military population is worth noting; these were not sedentary patients with mild discomfort. The evidence is controlled and positive but still limited in volume. Expect pain relief during weight-bearing and functional activities to improve within weeks when combined with appropriate rehabilitation exercises.
Post–Total Knee Arthroplasty
Evidence Rating: ★★★★ Strong
This is where the clinical specificity of the evidence is most striking. Bahrami et al. (2023) enrolled 45 patients after total knee replacement in a three-arm prospective RCT, and the outcomes were stark. The laser therapy group reached 116.8° of knee flexion at 3 months versus 92.3° for controls. That is 25 degrees of additional range of motion, which translates concretely: the difference between struggling to climb stairs and walking them normally. Swelling was significantly lower at 3 months, opioid consumption was reduced, and functional scores were significantly higher at all follow-ups.
Chia et al. (2025) confirmed the swelling finding through bioimpedance measurement and documented improved walking distance (27m vs 16m on the 2-minute walk test). Vassão et al. (2022) demonstrated that home-based LED photobiomodulation before and after TKA was feasible, with all participants pain-free at 6 weeks and no opioid use.
For someone planning or recovering from knee replacement, starting photobiomodulation in the perioperative period is supported by two RCTs and a feasibility study. Expect faster swelling resolution, improved range of motion during the critical early recovery window, and reduced need for opioid pain management. The therapy is safe to use alongside standard post-surgical rehabilitation.
Tendinopathy (Patellar, Quadriceps)
Evidence Rating: ★★ Emerging
No large RCTs exist specifically for patellar tendinopathy and photobiomodulation. The mechanistic evidence, though, is getting hard to ignore. Marcos et al. (2025) found that photobiomodulation actively promoted inflammation resolution through lipoxin receptor pathways: genuine resolution, meaning the tendon completes its healing cycle rather than stalling in chronic inflammation. Vedda et al. (2025) demonstrated that photobiomodulation reversed the collagen degradation and mechanical pain sensitivity caused by tendinopathy in animal models. Ryu et al. (2022) showed that 630nm LED increased human tendon cell migration by 3× versus control, directly relevant to tendon repair. Morimoto et al. (2013) treated 41 patients with various sports injuries and reported a 65.9% overall effectiveness rate, with patellar tendinopathy among the highest-response conditions.
The biological mechanisms photobiomodulation engages (collagen restoration, inflammation resolution, tenocyte proliferation) are precisely the processes that fail in chronic tendinopathy. For someone with chronic patellar or quadriceps tendinopathy that has not responded to rest or standard physiotherapy, this therapy addresses the failed-healing biology of the condition. Expect gradual improvement over weeks as inflammation resolves and collagen remodeling progresses. The evidence is mechanistically strong but awaits a knee-specific placebo-controlled trial for clinical confirmation.
Rheumatoid Arthritis (Knee)
Evidence Rating: ★★ Emerging
The RA evidence is more complicated, and it is worth being direct about why. Two meta-analyses examined photobiomodulation for rheumatoid arthritis, and they did not land in the same place. Salajegheh et al. (2024) found significant improvements in grip strength and reduced morning stiffness across 22 RCTs, though pain outcomes were inconsistent. Lourinho et al. (2023) analyzed 18 RCTs with 793 participants and found low-quality evidence that infrared laser was not superior to sham for pain in RA.
The mechanistic rationale is sound. Photobiomodulation modulates the same NF-κB and TNF-α pathways that drive RA inflammation, and Wang et al. (2025) demonstrated macrophage M1-to-M2 reprogramming in arthritic joint tissue. But the clinical translation to consistent pain reduction in RA has not matched the cellular promise.
RA in the knee is a different biological problem than OA. The immune system is attacking the joint, and while the evidence shows photobiomodulation can modulate that immune response at the cellular level, the clinical picture is uneven. Functional improvements (less morning stiffness, better grip strength) have been documented. Pain reduction is less reliable in the RA-specific literature than in OA. For someone with RA-driven knee pain, photobiomodulation is a complement to disease-modifying antirheumatic drugs (DMARDs), not a standalone approach. Expect modest functional improvements; pain reduction is possible but less consistently demonstrated.
Is Light Therapy Safe for Knee Pain Patients?
Across all knee-specific clinical trials reviewed, no serious adverse events have been attributed to photobiomodulation therapy. The 2025 umbrella review by Son et al. found no evidence of harm across 204 RCTs spanning multiple conditions. The 2024 Oliveira et al. systematic review of 10 knee OA RCTs confirmed the therapy's tolerability. The therapy is non-invasive, drug-free, does not interact with medications, and can be used alongside exercise, physical therapy, and standard medical care.
(For the complete safety evidence, see Photobiomodulation Safety for Knee Pain.)
Can You Use an LED Device Instead of a Clinical Laser?
The biological mechanisms of photobiomodulation are wavelength-dependent, not device-dependent. A photon at a given wavelength triggers the same mitochondrial response whether it originates from a laser or an LED. The 2021 Alqualo-Costa RCT, the largest knee-specific trial (168 patients), used an 850nm LED device and found significant, sustained pain reduction through 6 months.
(For the complete LED vs. laser evidence, see LED vs. Laser for Knee Pain.)
Conclusion: Applying the Research
At this point, the question isn't whether photobiomodulation works for knee osteoarthritis. It's how to optimize the delivery. A network meta-analysis ranking it first among all physical modalities for pain and function, an umbrella review of 204 RCTs placing knee OA disability among its strongest evidence domains; that evidence base demands clinical attention. What I find most compelling is the molecular data. We have human biomarker evidence now: reductions in cartilage-degrading enzymes and inflammatory cytokines measured directly in knee joint fluid after treatment. That's not symptom management. That's engaging the disease process.— Dr. William Carter, MD
The clinical evidence establishes that photobiomodulation works for knee pain. Treatment parameters determine outcomes. The 2019 Stausholm meta-analysis found that results are dose-dependent: adequate irradiance at appropriate wavelengths produces significant outcomes; underpowered protocols do not. The 2024 Fan et al. network meta-analysis identified 904–905nm as the most effective wavelength for knee pain, with 785–850nm also significantly outperforming sham. Joint treatment requires coverage across the full knee surface, not a single point of concentrated intensity.
Red and infrared light therapy addresses multiple biological drivers of knee pain simultaneously: cellular energy depletion, chronic inflammation, cartilage degradation, and pain signaling. It does not reverse advanced structural damage, and it does not replace medical management. But across more than two decades of clinical research, the evidence shows it is among the most effective non-pharmacological interventions available for knee pain, with a safety profile that allows sustained daily use and a multi-mechanism benefit profile that NSAIDs, cortisone injections, and single-modality physical therapies do not offer.
For a deeper understanding of how red light therapy works for other conditions that commonly overlap with knee pain, see our reviews of red light therapy for osteoarthritis and red light therapy for inflammation.
